Literature DB >> 15607625

Aquaporin-2 water channels in spontaneously hypertensive rats.

Michele Buemi1, Lorena Nostro, Giuseppe Di Pasquale, Emanuela Cavallaro, Alessio Sturiale, Fulvio Floccari, Carmela Aloisi, Antonella Ruello, Gioacchino Calapai, Francesco Corica, Nicola Frisina.   

Abstract

Vasopressin (AVP), an antidiuretic hormone, is known to induce hypervolemia and to regulate the renal expression of aquaporin-2 (AQP2) water channels, but it is not yet known whether the latter are involved in the pathogenesis of essential hypertension. The aim of the present study was therefore to make a comparative study of blood pressure (BP), urinary volume (UV), urinary osmolarity (uOsm), urinary AQP2 (uAQP2), and plasma AVP levels (PAVP) in male spontaneously hypertensive rats (SHR; n = 30) at 3, 7, and 12 weeks of age and in male Wistar-Kyoto rats (WKY, n = 30), also after the subcutaneous administration of OPC-31260 (OPC), a human AVP V(2) receptor antagonist. At 3 weeks, SHR had markedly higher uOsm and lower UV levels than WKY. At 7 weeks, SHR were hypertensive, showing increased uAQP2, PAVP, and uOsm levels and a decreased UV. At 12 weeks, no significant changes were observed in this condition. At 7 and 12 weeks of age, OPC-treated WKY rats showed significant reduction in BP and uOsm and increase in UV with respect to untreated animals. From 3 weeks of age, OPC-treated SHR presented significantly lower BP levels, higher UV levels, and lower uOsm than untreated animals. In treated WKY and SHR, uAQP2 levels were lower than in untreated animals. The PAVP appeared to be higher in OPC-treated rats from both strains. These findings suggest that AVP and the AQP2 are involved in the pathogenesis of hypertension in SHR.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15607625     DOI: 10.1016/j.amjhyper.2004.07.003

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  6 in total

1.  Evidence for a Prehypertensive Water Dysregulation Affecting the Development of Hypertension: Results of Very Early Treatment of Vasopressin V1 and V2 Antagonism in Spontaneously Hypertensive Rats.

Authors:  Ignazio Verzicco; Stefano Tedeschi; Gallia Graiani; Alice Bongrani; Maria Luisa Carnevali; Simona Dancelli; Jessica Zappa; Silvia Mattei; Achiropita Bovino; Stefania Cavazzini; Rossana Rocco; Anna Calvi; Barbara Palladini; Riccardo Volpi; Valentina Cannone; Pietro Coghi; Alberico Borghetti; Aderville Cabassi
Journal:  Front Cardiovasc Med       Date:  2022-06-01

2.  ANG II-induced hypertension in the VCD mouse model of menopause is prevented by estrogen replacement during perimenopause.

Authors:  Dennis P Pollow; Melissa J Romero-Aleshire; Jessica N Sanchez; John P Konhilas; Heddwen L Brooks
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-10-21       Impact factor: 3.619

3.  Abnormal increase in urinary aquaporin-2 excretion in response to hypertonic saline in essential hypertension.

Authors:  Carolina Cannillo Graffe; Jesper Nørgaard Bech; Thomas Guldager Lauridsen; Henrik Vase; Erling Bjerregaard Pedersen
Journal:  BMC Nephrol       Date:  2012-03-27       Impact factor: 2.388

4.  Attenuating Effects of Dieckol on Hypertensive Nephropathy in Spontaneously Hypertensive Rats.

Authors:  Myeongjoo Son; Seyeon Oh; Junwon Choi; Ji Tae Jang; Kuk Hui Son; Kyunghee Byun
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

5.  Comparative quantitation of aquaporin-2 and arginine vasopressin receptor-2 localizations among chronic kidney disease and healthy kidney in dogs.

Authors:  Pitchaya Matchimakul; Wanpitak Pongkan; Piyamat Kongtung; Raktham Mektrirat
Journal:  Vet World       Date:  2021-10-27

6.  Effect of volume expansion with hypertonic- and isotonic saline and isotonic glucose on sodium and water transport in the principal cells in the kidney.

Authors:  Janni M Jensen; Frank H Mose; Jesper N Bech; Soren Nielsen; Erling B Pedersen
Journal:  BMC Nephrol       Date:  2013-09-26       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.